angiodynamics

Canaccord Genuity

46th Annual Growth Conference

August 11, 2026

Jim Clemmer, President & CEO

Stephen Trowbridge, Executive Vice President & CFO

Forward looking statements

Notice Regarding Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "projects," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics' expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, tariffs, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2026. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

Notice Regarding Non-GAAP Financial Measures

Management uses non-GAAP measures to establish operational goals and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics' business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this presentation, AngioDynamics has reported pro forma results, adjusted EBITDA (income before interest, taxes, depreciation and amortization and stock-based compensation); adjusted net income and adjusted earnings per share. Management uses these measures in its internal analysis and review of operational performance. Management believes that these measures provide investors with useful information in comparing AngioDynamics' performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics' underlying business. Management encourages investors to review AngioDynamics' financial results prepared in accordance with GAAP to understand AngioDynamics' performance taking into account all relevant factors, including those that may only occur from time to time but have a material impact on AngioDynamics' financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP.

AngioDynamics

Our proven success positions us for sustained growth and profitability in key markets.

2020 - Today

Drove Performance and Built a More Dynamic Growth Focused Company

Sharpened Portfolio Focus

- Active portfolio management to scale high-growth MedTech opportunities

Accelerated Innovation

- Expanded MedTech leadership through innovation, strategic M&A, clinical investment, and meaningful physician engagement

Strengthened Financial Position

- Delivered accelerated growth, streamlined operations, and improved margin performance

Med Tech Growth & Sales Mix (%)



Today & Beyond

Positioned for Sustained Profitable Growth

Accelerating Commercial Investment

- Building a stronger go-to-market engine in Cardiovascular and Prostate to capture growth opportunities

Fueling Innovation

- Increasing R&D investment to deliver breakthrough technologies and long-term value

Expanding Market Potential

- Growing TAM as clinical data unlocks new indications across MedTech franchises

Robust Product Pipeline

- Leveraging leading platforms to accelerate innovation and support sustained expansion in attractive, high-growth markets

Unrivaled Innovation

Our synergistic portfolio is focused on providing comprehensive solutions to help treat patients within two of the largest global healthcare markets

	Cardiovascular Disease		Cancer
	ARTERIAL	VENOUS	
Med Tech	AURYON **Peripheral Artery Disease (PAD)** $800M U.S. TAM	ANGIOVAC, ALPHAVAC **Venous Thromboembolism (VTE)** $5.5B U.S. TAM	NANOKNIFE Irreversible Electroporation (IRE) PROSTATE **Prostate Care** $930M U.S. TAM
Med Device	Uni-Fuse, Mariner, ADX, VenaCure EVLT, Soft-Vu Angiographic Catheters, Accu-Vu, MINI STICK MAX		SmartPort+, Solero, Habib 4X, IsoLoc

Demonstrated Med Tech Growth Execution

Pro Forma Fiscal Year Net Sales ($M)



Cardiovascular Arterial

Since its launch in September 2020, Auryon has been used in nearly 180,000 procedures and surpassed $255M in cumulative sales

MARKET DYNAMICS



Peripheral Artery Disease (PAD)
• Hospital market growth fuels ASP stability • New and expanded reimbursement coverage solidifies atherectomy's place in treatment algorithms • AMBITION BTK further positions us for market expansion

Auryon is versatile and effective at treating all types of lesions both through the femoral and radial approaches

Comprehensive Treatment Capability

- Effectively addresses all lesion types, including severe calcification and in-stent restenosis

Precision and Safety

- Optimized technology delivers energy without thermal damage, with built-in aspiration to minimize embolization risk

Efficiency and Proven Outcomes

- Portable, easy-to-use system with clinically validated performance and high patency rates

AURYON

Cardiovascular Venous

Venous Thromboembolism (VTE) represents an attractive, high growth, underpenetrated market opportunity

MARKET DYNAMICS



PE + DVT = Venous Thromboembolism (VTE)

- Mechanical Thrombectomy for **PE** is estimated to have penetrated ~20% of the TAM
- Mechanical Thrombectomy for **DVT** is estimated to have penetrated ~15% of the TAM

Right Heart Cardiac Thrombus & Emboli

- Growth is driven by rising increase in endocarditis and an aging population
- More interventionalists embrace percutaneous techniques and the structural heart market is expanding

ANGIOVAC

ALPHAVAC

Mechanical Thrombectomy

Proprietary funnel cannula technology with the ability to have aspiration and simultaneous reinfusion with AngioVac or off-circuit manual aspiration control with AlphaVac

AlphaVac Indicated for Treatment of Pulmonary Embolism

ALPHAVAC

- Minimally invasive treatment used to treat PE and remove large blood clots, or thrombi, and other material from the venous system (veins), including the pulmonary arteries
- Manual aspiration control enables precise suction, enhanced physician control, and improved maneuverability for wireless navigation between the PA's



Complete system significantly improving reduction in clot burden vs. competitive technologies



*Actual case result

Aspiration & Simultaneous Reinfusion

ANGIOVAC

- Minimally invasive treatment used to remove large blood clots, or thrombi, and other material from the venous system (veins)
- On-circuit aspiration provides surgical results via percutaneous access by simultaneously reinfusing blood back in the patient's body, minimizing blood loss

APEX – AV Pivotal Study

AlphaVac received FDA clearance for PE following APEX-AV study demonstrating efficacy and significantly improved reduction in clot burden vs. competitive technologies

APEX-AV

Number of Sites	**25 US Sites**
Number of Patients	**122**
Timeline	**Oct. 2022 – Dec 2023**

Significant reduction in the RV/LV ratio
- Significant improvement in the RV function

Significant reduction in clot burden
- Large funnel size (33 Fr) may aid in reducing the clot burden

Procedure efficiency
- Atraumatic tip provides easy and efficient navigation in the PAs
- Ability to minimize blood loss
- Short procedure time

	APEX (AngioDynamics)	FLARE (Inari/Stryker)	EXTRACT-PE (Penumbra)
Reduction in Clot Burden	**35.1%**	9.3%	11.3%

Prostate Cancer

Backed by real world evidence and compelling clinical data, NanoKnife is a one-of-a-kind technology poised to change the standard of care of men with prostate cancer

MARKET DYNAMICS



Prostate Cancer is Prevalent, On the Rise & Debilitating

- The most diagnosed male cancer in 112 countries, including the U.S.
- Incidence projected to double by 2040
- Focal therapy is less than 7% penetrated into the Intermediate Risk addressable market

Only Function-preserving Therapy that Uses Electricity to Destroy Prostate Tumors

- Destroys targeted tissue with precise margins, preserving vital structures and tissue integrity
- Backed by real world evidence and compelling clinical data, NanoKnife is a one-of-a-kind technology poised to change the standard of care of men with prostate cancer
- NanoKnife safely & effectively treats prostate tumors while avoiding the high incidence of erectile dysfunction and incontinence associated with radical surgery and radiation

NANOKNIFE
Irreversible Electroporation (IRE) PROSTATE



Irreversible Electroporation (IRE)

Preserves the underlying structure of tissue giving physicians a more precise tool

NanoKnife
Irreversible Electroporation (IRE) PROSTATE

- **Only IRE device FDA cleared** for prostate tissue
- Efficiently **treats all segments** of the prostate
- **Easy clinical integration**
- Significantly **reduces quality of life side-effects** caused by other therapeutic options



PROBE PLACEMENT

NanoKnife can be confidently used in all segments of an organ.



DECELLULARIZATION

Destroys targeted tissue with precise treatment margins.



NON-THERMAL

Spares vital structures by retaining the structural integrity of tissue.[3]



REVASCULARIZATION

Facilitates functional tissue regeneration post-ablation.

PRESERVE Pivotal Study

NanoKnife safely & effectively treats prostate tumors while avoiding the high incidence of erectile dysfunction and incontinence associated with radical surgery and radiation

PRESERVE

Number of Sites	**17 US Sites**
Number of Patients	**121**
Primary Endpoint Follow Up	**12 Months**

Efficacy

84% of patients were free from clinically significant in-field disease

Safety

3.3% of patients had a device related SAE, all of which resolved

Change from baseline at 1 year

	IRE	Radical Surgery	Radiation Therapy
Erectile Function	**(9%)**	(51%)	(30%)
Urinary Continence	**(1.2%)**	(41%)	(8%)

24-month Data: No New Treatment Failures; 97% with PSA Below Baseline

FY 2026 Key Takeaways

Continued commercial and operational execution drives AngioDynamics' accelerated and profitable growth.

YoY Revenue Growth*	**Total** +9.4%	**Med Tech** +18.4%	**Med Device** +2.5%
Med Tech YoY Revenue Growth*	**Auryon** +17.7%	**Mech Thrombectomy** 13.4%	**NanoKnife Probes** +28.7%

Continued Execution

- Net sales of $320.2M, +9.4% YoY growth
- Med Tech segment sales of $150.0M, +18.4% YoY growth
- Med Device segment sales of $170.2M, +2.5% YoY growth

Focus on Profitability

- Pro forma Adjusted EBITDA** of $13.2M

Balance Sheet Strength

- Ended fiscal year with $53.9M in Cash
- Zero debt with flexibility of revolving line of credit
- Generated ~$3.1M of cash from operations in the year
- Will generate positive cash flow from operations in FY27

*All growth rates are pro forma

** Pro forma Adjusted EBITDA excludes the $5.0 million milestone payment received from Spectrum Vascular in Q3 of FY 2026

Fiscal Year 2027 Guidance

supported by balance sheet strength

FY 2026 Net Sales ($M)



FY 2027 Financial Guidance*

Metric	Current Guidance
Net Sales	**$336.0M - $341.0M**
Med Tech Net Sales Growth	*+12% - 15%*
Med Device Net Sales Growth	*Flat*
Gross Margin	**54% – 55%**
Adjusted EBITDA	**+$13.0M - $16.0M**
Adjusted EPS	**($0.29) – ($0.24)**

*Guidance was issued in conjunction with fiscal Q4 FY 2026 earnings call on July 14, 2026

Strong Product & Clinical Pipeline

Leveraging our leading platforms to fuel innovation, market expansion, and long-term shareholder value in key growth markets

Platform	FY26 & Earlier $7.2B US TAM	FY27 – FY31 $10.9B US TAM
AURYON	**Peripheral Artery Disease: $800M US TAM**	
		IVL Indication
		DVT: $2.8B US TAM
		Coronary: $900M US TAM
ALPHAVAC / ANGIOVAC	Pulmonary Embolism: $2.4B US TAM	
	Right Heart: $280M US TAM	
		Infective Endocarditis Indication
		DVT: $2.8B US TAM
		Left Heart: $760M US TAM
NANOKNIFE Irreversible Electroporation (IRE) PROSTATE	**Prostate Cancer: $930M US TAM**	
		BPH: $1.9B US TAM

Ongoing Clinical Initiatives to Support Growth

	Initiative	Purpose	Overview
AURYON	AMBITION BTK	Increased utilization within the below the knee critical limb ischemia (CLI) disease state	A randomized controlled trial of the Auryon Atherectomy System + balloon angioplasty vs. standard angioplasty alone for below-the-knee lesions with critical limb ischemia (up to 224 patients / 30 sites + 1,500-patient registry).
ALPHAVAC	RECOVER-AV	Increased European adoption	A multi-center, multi-national, single-arm study of the AlphaVac F1885 System for mechanical thrombectomy in the treatment of acute, intermediate-risk pulmonary embolism (PE).
ALPHAVAC	APEX-Return	Enables collection, filtration, and reinfusion of aspirated blood during thrombectomy; addresses market feedback on blood loss	An IDE-approved study of the AlphaReturn blood management system, evaluating key safety and effectiveness endpoints, including device-related adverse events and procedural outcomes.
ANGIOVAC	PAVE	Indication expansion into right-sided infective endocarditis (RSIE)	A prospective, single-arm, multicenter feasibility trial that will enroll up to 30 patients with RSIE at up to six U.S. centers. In August 2023, the AngioVac System received an FDA Breakthrough Device designation for the removal of right heart vegetation.
NANOKNIFE Irreversible Electroporation (IRE) PROSTATE	RELIEF	Indication expansion into benign prostatic hyperplasia (BPH)	A feasibility study evaluating irreversible electroporation (IRE), for the treatment of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH).
	IRRADIANT	Expanded utilization in prostate cancer treatment continuum	A randomized controlled trial evaluating a boost using IRE technology to a standard radiation therapy boost, both paired with a reduced course of whole gland radiation therapy, across 224 patients at Memorial Sloan Kettering (MSK).

AngioDynamics Investment Summary

Attractive MedTech Platforms in High-Value Markets

Our MedTech segment operates in large, growing clinical markets, supported by differentiated technologies and proven clinical outcomes.

Demonstrated Execution and Portfolio Discipline

We have a strong track record of active portfolio management, disciplined R&D investment, successful clinical and regulatory expansion, and customer-centric sales and marketing execution.

Self-Funded Growth Model

Our Med Device segment generates cash flow that funds targeted investments to accelerate MedTech innovation and growth.

Strong, Debt-Free Balance Sheet

We maintain a solid financial foundation with no debt, providing flexibility to invest, scale, and pursue strategic opportunities.

Clear Path to Profitability and Cash Generation

We achieved adjusted EBITDA positivity in FY2025, built on that progress in FY2026, and are now advancing toward free cash flow positivity in FY2027, reflecting improving operating leverage and margin expansion.

Positioned for Sustainable, Long-Term Value Creation

With focused strategy, financial strength, and innovation-driven growth, AngioDynamics is well positioned to deliver durable revenue growth and profitability over the long term.